Sharon T. Sullivan

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 483 citations · Full text

Hematological Malignancy, Magnetismm-3 Trial Results, Medicine +13

In Vitro Comparison of Topical Microbicides for Prevention of Human Immunodeficiency Virus Type 1 Transmission

Charlene S. Dezzutti, V. Nicole James, Artur Ramos et al. · Antimicrobial Agents and Chemotherapy · 2004 · 135 citations · Full text

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar J. Bahlis, Michael H. Tomasson, Mohamad Mohty et al. · Blood · 2022 · 50 citations

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Michael H. Tomasson, Shinsuke Iida, Rubén Niesvizky et al. · HemaSphere · 2024 · 43 citations · Full text

Immunology, Immunotherapeutics, Immunotherapy +19

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

Nina D. Wagner‐Johnston, André Goy, Maria Alma Rodriguez et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 39 citations

Transplant Eligible Patients, Immunology, Pathology +16